A Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of NT-I7 (efineptakin alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects with Relapsed/Refractory Large B-cell Lymphoma

• Protocol Number: 202512084
• Principal Investigator: Crees, Zachary
• Cancer Types: Gene & Cellular Immunotherapy

Learn more about this study at: clinicaltrials.gov